AEG-POWER-SOLUTIONS
AEG Power Solutions (FWB:3W9K), a global provider of power electronic systems and solutions for industrial power supplies and renewable energy applications, announces the 20th anniversary of its Transokraft inverter.
The latest version of the system was re-launched in 2012 and includes new software-free features; this absence of embedded software prevents any risk of digital instability, thus providing the highest level of security and reliability for the equipment.
For two decades, Transokraft inverters have helped to secure the power supply for critical infrastructure and processes around the globe. Transokraft was designed to comply with the most stringent standards of nuclear power generation applications, and the inverters are certified for quality insurance accordingly (KTA1401). They rank first in class of their category in qualification tests where they have proven their high levels of resistance to seismic and climatic shocks, as well as their functional capacity under electromagnetic disturbances in EMC tests.
Transokraft equips many of the world’s nuclear power plants, including Heysham in the UK, Oskarshamn in Sweden, Olkiluoto in Finland, Pickering in Canada, Atucha in Argentina, Gösgen in Switzerland, Taishan in China.
“Twenty years ago, we introduced Transokraft to help secure the power supply of nuclear power plants and other critical applications – and customers immediately recognised its reliability and ability to help provide a dependable, safe solution even in the most challenging operational conditions,” says Rudolf Poeppelbaum, Sales Manager Power Generation at AEG Power Solutions. “Combined with AEG PS’ service expertise and unrivalled technical support, we expect Transokraft to carry on serving our customers for decades to come.”
Transokraft is part of an extensive range of products designed by AEG Power Solutions to meet power generation industry needs and the specific requirements of nuclear applications. Devices in the range include the Profitec S and SN1 battery chargers, as well as switch mode power supply modules. The portfolio of available products enables customers to benefit from a single certified source, complying with the same standards. All systems can be fully customized.
As proven by their track record, the rugged and highly reliable technology of this range results in systems that can be supported for a minimum of 20 years. The consistency in design minimizes spare part requirements and provides operational simplicity.
No. No. No.
About AEG Power Solutions
AEG Power Solutions (AEG PS) Group is a global provider of power electronics systems and solutions for all industrial and demanding commercial power requirements offering one of the most comprehensive product and service portfolios in the area of uninterruptible power supply and power management. Thanks to its distinctive expertise bridging both AC and DC power technologies and spanning the worlds of both conventional and renewable energy, the company creates innovative solutions for next generation distributed power generation.
AEG Power Solutions Group is the sole subsidiary of the holding company 3W Power S.A. (WKN A114Z9) / ISINLU1072910919), based in Luxembourg. The Group is headquartered in Zwanenburg in the Netherlands. The shares of 3W Power are admitted to trading on Frankfurt Stock Exchange (ticker symbol: 3W9K).
For more information, visit www.aegps.com
This communication does not constitute an offer or the solicitation
of an offer to buy, sell or exchange any securities of 3W Power. This
communication contains forward-looking statements which include, inter
alia, statements expressing our expectations, intentions, projections,
estimates, and assumptions. These forward-looking statements are based
on the reasonable evaluation and opinion of the management but are
subject to risks and uncertainties which are beyond the control of 3W
Power and, as a general rule, difficult to predict. The management and
the company cannot and do not, under any circumstances, guarantee future
results or performance of 3W Power and the actual results of 3W Power
may materially differ from the information expressed or implied in the
forward-looking statements. As a result, investors are cautioned against
relying on the forward-looking statements contained herein as a basis
for their investment decisions regarding 3W Power.
3W Power
undertakes no obligation to update or revise any forward-looking
statement contained herein.
Photos/Multimedia Gallery Available: http://www.businesswire.com/multimedia/home/20141126005228/en/
Contact:
Press contact:
Ute von Cranach, Phone.: +49 2902 763 256
Mobile:
+49 170 574 9094
Marketing Communications
AEG Power Solutions
Email:
ute.voncranach@aegps.com
or
Agency
contact :
Gerlinde Knöpfle, Phone: +49 89 6491 3634-12
Mobile:
+49 160 9512 7238
embedded PR
Müllerstr. 44 Rgb., 80469 München
Email:
gk@embedded-pr.de
Link:
Information om Business Wire
Følg pressemeddelelser fra Business Wire
Skriv dig op her, og modtag pressemeddelelser på e-mail. Indtast din e-mail, klik på abonner, og følg instruktionerne i den udsendte e-mail.
Flere pressemeddelelser fra Business Wire
4Moving Biotech Enrolls First Patient in Phase 2a Trial of 4P004, a Potential First-in-Class GLP-1 Therapy for Knee Osteoarthritis16.7.2025 07:00:00 CEST | Press release
- First patient enrolled in INFLAM MOTION, a global randomized Phase 2a trial including 129 knee osteoarthritis patients - 4P004 to be evaluated over 3 months for dual efficacy: symptom relief and synovial health improvement via contrast-enhanced MRI - Topline results expected in the second half of 2026 4Moving Biotech (4MB), a spin-off of 4P-Pharma dedicated to developing first-in-class treatments that modify the natural course of knee osteoarthritis (OA), today announced that the first patient has been enrolled in Phase 2a clinical trial, INFLAM MOTION. The study will evaluate 4P004, an intra-articular GLP-1 analog, as a potential first-in-class therapeutic candidate for knee osteoarthritis. INFLAM MOTION is a multicenter, randomized, double-blind, placebo-controlled Phase 2a trial planned to be conducted across Europe, the United States, and Canada. A total of 129 patients worldwide diagnosed with knee OA will be enrolled to evaluate, for the first time in humans, the efficacy of 4P
Belkin Achieves Qi2.2 Certification for Its Upcoming Products, Unlocking the Future of 25W Wireless Charging15.7.2025 19:06:00 CEST | Press release
With Qi2.2 certification, Belkin reinforces its commitment to quality, safety, and performance for the next generation of wireless charging Belkin, a leading consumer electronics brand for over 40 years, today announced it has received official Qi2.2 certification from the Wireless Power Consortium (WPC) for its upcoming products. As one of the first accessory brands to deliver Qi2.2-certified devices, Belkin is helping bring the next generation of wireless charging to market – enabling faster wireless charging speeds, broader compatibility, and improved performance for consumers. Belkin’s close partnership with the WPC since 2015 has been instrumental in bringing these advancements to consumers. As an early adopter and long-time contributor to WPC standards, Belkin was selected as one of a small group of trusted manufacturers to test and certify Qi2.2 products ahead of the broader industry rollout. All Belkin products undergo rigorous safety, quality, and performance testing. The comp
Cessna Grand Caravan EX to Feature New Executive Interior Options, Expanding Opportunities for Elevated Missions15.7.2025 18:05:00 CEST | Press release
The legendary Cessna Grand Caravan EX will now feature three new executive interior schemes for customers to select when designing their aircraft cabin. The Lunar, Obsidian and Saddle Sport interiors join the existing Canyon and Savanna schemes, providing a broader range of standard choices. The new interior options are available to customers starting this month and allow them to further tailor the interior of their aircraft based on their personal preference or mission. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250715021096/en/ Cessna Grand Caravan EX to feature new executive interior options, expanding opportunities for elevated missions (Photo Credit: Textron Aviation) The Cessna Grand Caravan EX is designed and manufactured by Textron Aviation Inc., a Textron Inc. (NYSE:TXT) company. Premium versions of each of the new interiors are also available, featuring quilted seat stitching and plush carpet, providing an elev
7 Million Tokens Sells Out in less than One Hour—$MBG Token Pre-Sale Shatters Expectations15.7.2025 17:27:00 CEST | Press release
MultiBank Group, the world’s largest and most regulated financial derivatives institution, has set a new benchmark in digital asset launches. The Group’s $MBG Token Pre-Sale sold out in less than one hour with all 7 million tokens fully subscribed across MultiBank.io and Uniswap. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250715055611/en/ The Group’s $MBG Token Pre-Sale sold out in less than one hour with all 7 million tokens fully subscribed across MultiBank.io and Uniswap. Commenting on the success of the Pre-Sale, Naser Taher, Founder and Chairman of MultiBank Group, said: “The sell-out of our initial $MBG Token offering in less than one hour is a decisive validation of our vision. In a market saturated with speculation, the response we received confirms that institutional-grade transparency, regulatory integrity, and asset-backed value are what investors are now demanding. $MBG is here for the long term, reflecting t
First Patient Enrolled in National Cancer Institute’s Vanguard Study Evaluating Guardant Health’s Shield Multi-Cancer Detection Test15.7.2025 17:01:00 CEST | Press release
Study addressing feasibility of using multi-cancer detection tests in future trials aims to enroll up to 24,000 participantsShield MCD reviewed by FDA as part of NCI’s investigational device exemption (IDE) Guardant Health, Inc. (Nasdaq: GH), a leading precision oncology company, today announced that patient enrollment has begun in the National Cancer Institute (NCI)’s Vanguard Study to evaluate emerging multi-cancer detection (MCD) technology. Guardant’s Shield™ MCD test was selected for use in the four-year study, which aims to enroll up to 24,000 patients and evaluate the use of MCD tests—blood tests that can screen for several types of cancer simultaneously—in future randomized controlled trials. Guardant’s Shield MCD test was chosen for the study based on the overall performance of its Shield platform in detecting 10 cancer types, including lung, breast, colorectal, prostate, bladder, ovarian, pancreatic, esophageal, liver and gastric. The data were presented at the 2025 American
I vores nyhedsrum kan du læse alle vores pressemeddelelser, tilgå materiale i form af billeder og dokumenter samt finde vores kontaktoplysninger.
Besøg vores nyhedsrum